• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在一组阿霉素耐药细胞系中选择具有较少DNA拓扑异构酶IIα基因拷贝的亚群。

Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel.

作者信息

Withoff S, Keith W N, Knol A J, Coutts J C, Hoare S F, Mulder N H, de Vries E G

机构信息

Department of Internal Medicine, University Hospital Groningen, The Netherlands.

出版信息

Br J Cancer. 1996 Aug;74(4):502-7. doi: 10.1038/bjc.1996.393.

DOI:10.1038/bjc.1996.393
PMID:8761362
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2074676/
Abstract

A panel of doxorubicin-resistant sublines of the human small-cell lung carcinoma cell line GLC4 displays decreasing DNA topoisomerase II alpha (TopoII alpha) mRNA levels with increasing resistance. In the present study we describe how this decrease may be regulated. No significant differences in TopoII alpha mRNA stability or gene arrangement were found, using mRNA slot-blotting and Southern blotting, in the most resistant cell line compared with the parental cell line. To investigate if TopoII alpha gene copy loss contributed to the mRNA decrease, fluorescence in situ hybridisation using a TopoII alpha-specific probe was performed. During doxorubicin resistance development, the composition of the population in each cell line shifted with increasing resistance, from a population in which most cells contain three TopoII alpha gene copies (GLC4) to a population in which most cells contain only two copies. A partial revertant of the most resistant cell line displayed a shift back to the original situation. We conclude that the TopoII alpha gene copy number decrease per cell line is in good agreement with the decreased TopoII alpha mRNA and protein levels, and TopoII activity levels in these cell lines which were described previously.

摘要

人小细胞肺癌细胞系GLC4的一组阿霉素耐药亚系显示,随着耐药性增加,DNA拓扑异构酶IIα(TopoIIα)mRNA水平降低。在本研究中,我们描述了这种降低可能是如何被调控的。使用mRNA斑点杂交和Southern杂交,在最耐药的细胞系与亲代细胞系之间,未发现TopoIIα mRNA稳定性或基因排列存在显著差异。为了研究TopoIIα基因拷贝数缺失是否导致mRNA降低,使用TopoIIα特异性探针进行了荧光原位杂交。在阿霉素耐药性发展过程中,每个细胞系中群体的组成随着耐药性增加而发生变化,从大多数细胞含有三个TopoIIα基因拷贝的群体(GLC4)转变为大多数细胞仅含有两个拷贝的群体。最耐药细胞系的部分回复突变体显示出向原始状态的转变。我们得出结论,每个细胞系中TopoIIα基因拷贝数的减少与这些细胞系中先前描述的TopoIIα mRNA和蛋白质水平以及TopoII活性水平的降低高度一致。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68af/2074676/60792a32ad5d/brjcancer00020-0014-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68af/2074676/3280680586dd/brjcancer00020-0014-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68af/2074676/60792a32ad5d/brjcancer00020-0014-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68af/2074676/3280680586dd/brjcancer00020-0014-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/68af/2074676/60792a32ad5d/brjcancer00020-0014-b.jpg

相似文献

1
Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel.在一组阿霉素耐药细胞系中选择具有较少DNA拓扑异构酶IIα基因拷贝的亚群。
Br J Cancer. 1996 Aug;74(4):502-7. doi: 10.1038/bjc.1996.393.
2
Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.DNA拓扑异构酶IIα和-β在人小细胞肺癌细胞系GLC4的P-糖蛋白和多药耐药相关蛋白阴性的VM26、mAMSA及米托蒽醌耐药亚系中的差异表达
Br J Cancer. 1996 Dec;74(12):1869-76. doi: 10.1038/bjc.1996.647.
3
Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.使用聚合酶链反应辅助转录物滴定分析法对小细胞肺癌细胞系及两个耐药亚系中的DNA拓扑异构酶IIα信使核糖核酸水平进行定量分析。
Lab Invest. 1994 Jul;71(1):61-6.
4
Enhanced sensitivity to tumor necrosis factor-alpha in doxorubicin-resistant tumor cell lines due to down-regulated c-erbB2.由于c-erbB2下调,阿霉素耐药肿瘤细胞系对肿瘤坏死因子-α的敏感性增强。
Int J Cancer. 1998 Jul 3;77(1):101-6. doi: 10.1002/(sici)1097-0215(19980703)77:1<101::aid-ijc16>3.0.co;2-h.
5
Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance.人小细胞肺癌GLC4亚系中与阿霉素耐药性增加相关的因素。
Int J Cancer. 1995 May 4;61(3):375-80. doi: 10.1002/ijc.2910610317.
6
Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.拓扑异构酶IIα的扩增和缺失与ErbB-2扩增相关,并影响乳腺癌对拓扑异构酶II抑制剂阿霉素的敏感性。
Am J Pathol. 2000 Mar;156(3):839-47. doi: 10.1016/s0002-9440(10)64952-8.
7
Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.在依托泊苷筛选出的耐药性小细胞肺癌细胞系中拓扑异构酶IIα发生改变。
Cancer Res. 1993 Oct 15;53(20):4866-73.
8
Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.DNA拓扑异构酶II的表达降低赋予了从一名患者的难治性肿瘤建立的小细胞肺癌细胞系以及通过体外筛选得到的细胞系对依托泊苷(VP - 16)的抗性。
Oncol Res. 1996;8(6):229-38.
9
Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposide.对依托泊苷耐药的人肾癌细胞系中拓扑异构酶IIα水平降低。
J Cancer Res Clin Oncol. 1997;123(10):546-54. doi: 10.1007/s004320050103.
10
Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing.在一个经依托泊苷筛选的肺癌细胞系中,拓扑异构酶IIα的两种羧基末端截短的胞质形式是由部分基因缺失和可变剪接产生的。
Biochemistry. 1997 May 13;36(19):5868-77. doi: 10.1021/bi962400y.

引用本文的文献

1
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.根据患者 TOP2A 状态,对 HER2+BC 患者采用新辅助蒽环类药物(5-FEC)或蒽环类药物-free(多西紫杉醇/卡铂)化疗联合曲妥珠单抗和帕妥珠单抗:一项多中心、开放标签、非随机的 II 期试验。
Breast Cancer Res Treat. 2024 Jun;205(2):267-279. doi: 10.1007/s10549-024-07285-y. Epub 2024 Mar 7.
2
A careful reassessment of anthracycline use in curable breast cancer.对蒽环类药物在可治愈性乳腺癌治疗中的应用进行仔细重新评估。
NPJ Breast Cancer. 2021 Oct 8;7(1):134. doi: 10.1038/s41523-021-00342-5.
3

本文引用的文献

1
Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes.拓扑异构酶IIα和β在携带扩增的拓扑异构酶IIα和视黄酸受体α基因的腺癌细胞系中的表达
Br J Cancer. 1993 Oct;68(4):793-800. doi: 10.1038/bjc.1993.430.
2
Drug resistance associated with altered DNA topoisomerase II.与DNA拓扑异构酶II改变相关的耐药性。
Adv Enzyme Regul. 1993;33:113-27. doi: 10.1016/0065-2571(93)90012-3.
3
Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases.
PROGNOSTIC VALUE OF TOPOISOMERASE 2-ALPHA AND B-MYB IN EARLY BREAST CANCER TREATED WITH ADJUVANT CHEMOTHERAPY.
辅助化疗治疗早期乳腺癌中拓扑异构酶 2-α 和 B-Myb 的预后价值。
Acta Clin Croat. 2021 Mar;60(1):16-24. doi: 10.20471/acc.2021.60.01.03.
4
Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies.聚合物纳米载体:阿霉素治疗的一次变革。
Materials (Basel). 2021 Apr 22;14(9):2135. doi: 10.3390/ma14092135.
5
Biological indicators of chemoresistance: an ex vivo analysis of γH2AX and expression in feline injection-site sarcomas.化疗耐药的生物学指标:猫注射部位肉瘤中γH2AX及[此处原文可能缺失部分内容]表达的体外分析
Cancer Cell Int. 2018 Nov 22;18:192. doi: 10.1186/s12935-018-0690-0. eCollection 2018.
6
High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy.在接受R-CHOP化疗且国际预后指数较低的弥漫性大B细胞淋巴瘤患者中,Bcl-2的高表达预示着不良预后。
Int J Hematol. 2016 Feb;103(2):210-8. doi: 10.1007/s12185-015-1911-0. Epub 2015 Nov 19.
7
HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics.人表皮生长因子受体2/神经(HER2/neu)、拓扑异构酶2a、雌激素和孕激素受体:原发性乳腺癌与转移性腋窝淋巴结在表达及扩增特征上的不一致性
Breast Care (Basel). 2012 Dec;7(6):465-70. doi: 10.1159/000345467.
8
Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.碳酸酐酶 IX 是早期乳腺癌中多柔比星耐药的预测标志物,与 HER2 和 TOP2A 扩增无关。
Br J Cancer. 2012 Feb 28;106(5):916-22. doi: 10.1038/bjc.2012.32. Epub 2012 Feb 14.
9
Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.拓扑异构酶 2α 基因转录水平较高的胶质母细胞瘤患者接受替莫唑胺化疗的预后较好:替莫唑胺是拓扑异构酶 2 抑制剂。
J Neurooncol. 2012 Apr;107(2):289-97. doi: 10.1007/s11060-011-0758-3. Epub 2011 Nov 19.
10
Novel molecular markers of malignancy in histologically normal and benign breast.组织学正常及良性乳腺中恶性肿瘤的新型分子标志物
Patholog Res Int. 2011;2011:489064. doi: 10.4061/2011/489064. Epub 2011 Jul 10.
新型海拉细胞拓扑异构酶II是IIβ亚型:完整编码序列及其与其他II型拓扑异构酶的同源性。
Biochim Biophys Acta. 1993 Mar 20;1172(3):283-91. doi: 10.1016/0167-4781(93)90215-y.
4
Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.拓扑异构酶II作为VM-26和4'-(9-吖啶基氨基)甲磺酰间茴香胺在非典型多药耐药人小细胞肺癌细胞中的作用靶点。
Cancer Res. 1993 Mar 1;53(5):1064-71.
5
Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions.不同DNA拓扑异构酶在HeLa和K562细胞核及亚核组分中的离散定位。
Exp Cell Res. 1994 Feb;210(2):336-48. doi: 10.1006/excr.1994.1046.
6
Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase.两种形式的DNA拓扑异构酶II表达的生长状态和细胞周期依赖性波动以及M期高分子量形式的可能特异性修饰。
J Biol Chem. 1994 Jan 14;269(2):1173-6.
7
Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy.人类肿瘤中拓扑异构酶I信使核糖核酸、蛋白质及催化活性的升高:肿瘤类型特异性的证明及其对癌症化疗的意义
Cancer Res. 1994 Jan 15;54(2):539-46.
8
Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.在对依托泊苷产生抗性的人白血病K562细胞中基因表达的改变。
Biochem Pharmacol. 1993 Dec 3;46(11):2007-20. doi: 10.1016/0006-2952(93)90643-b.
9
Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20.乳腺癌中erbB2、拓扑异构酶IIα和视黄酸受体α基因的共同扩增以及20号染色体上拓扑异构酶I的等位基因缺失。
Eur J Cancer. 1993;29A(10):1469-75. doi: 10.1016/0959-8049(93)90022-8.
10
Translocation (3;21)(q26;q22) in therapy-related myelodysplasia following drugs targeting DNA-topoisomerase II combined with alkylating agents, and in myeloproliferative disorders undergoing spontaneous leukemic transformation.
Cancer Genet Cytogenet. 1994 Aug;76(1):50-5. doi: 10.1016/0165-4608(94)90071-x.